Either alone or in combination with innate or adaptive strategies, the development of unique ILC-mediated therapies can bring forth new ways to improve efficacy as well as to overcome resistances to the current standard of care in melanoma and other cancers, with the ultimate goal of improving patient outcomes. The gene discussed is CCL27; the disease is cancer.